Fig. 1: Selection of human Pfs48/45-specific mAbs and development of a Pfs48/45 construct for structural studies.
a, TRA of mAbs in SMFA with Pf NF54 and Anopheles stephensi mosquitoes. Multiple concentrations of each mAb were tested in four to six separate SMFA experiments that are represented by different symbols. IC80 values were calculated using linear regression analysis and are shown above each graph, including 95% confidence intervals. TRA values above 99.5% were not included in the analyses. b, Binding of mAbs to live female Pf NF54 gametes by flow cytometry. Data points are the means of two experiments with three technical replicates each. Data from each experiment were normalized for the mean fluorescence intensity (MFI) of each mAb at the highest concentration tested. Bars represent the s.e.m. Non-linear regression curves were fitted to calculate EC50 binding values; EC50 values are shown above each graph with 95% confidence intervals. c, Construct schematics and size-exclusion chromatography profiles of full-length Pfs48/45, stabilized Pfs48/45 mAgE2 (with p.G397L, p.H308Y, p.I402V, p.S361R and p.D373S), and stabilized Pfs48/45 mAgE2 linked to a scTB31F Fab (Pfs48/45 mAgE2-scTB31F, top; abbreviated as Pfs48/45-scTB31F hereafter). Y-axis indicates milli-absorbance units (mA.U.) d, BLI binding curves of RUPA-58, RUPA-154, and RUPA-44 Fabs to Pfs48/45-scTB31F.
